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ABSTRACT
Infertility has become an increasingly common health problem and has been estimated to affect approximately 10% of 
women in the reproductive age. Due to its high prevalence, it has been deemed a social disease by the World Health Or-
ganization (WHO). The causes of infertility are numerous and vary from person to person. As for treatment, the three main 
therapeutic strategies include pharmacological therapy, surgical therapy — mostly endoscopy, and assisted reproductive 
technology (ART). Recent decades have witnessed great progress in ART, resulting in successful treatment of the previ-
ously untreatable cases, particularly in the field of fertility preservation, preimplantation screening for aneuploidy, uterine 
transplantations and mitochondrial replacement techniques as prevention against a number of severe diseases. Regardless, 
ART treatment does not guarantee pregnancy and live birth. The success rate is much smaller as compared to the failure 
rate, it being among its most important limitations. Embryo implantation is an extremely complex process and represents 
the most critical step of the reproduction process in humans. Attempts to evaluate endometrial receptivity and strategies 
for its correction have been discussed. The search for new effective predictors of an individual prognosis remains a crucial 
challenge for the contemporary reproductive medicine. 
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Infertility constitutes a significant challenge for the con-
temporary reproductive medicine. According to the World 
Health Organization (WHO), infertility is a disease entity 
and, due to its prevalence, was deemed a social disease. 
Furthermore, it is considered as a specific and unique health 
problem because it always concerns two people simultane-
ously: a woman and a man. Individually, they can be in the 
best of mental and physical health but as a couple, who 
wishes to conceive and fails, they may face the problem of 
infertility. The desire to form a family and produce progeny 
is a natural human need and, as such, has been included in 
the Universal Declaration of Human Rights. International es-
timates on the prevalence of infertility and treatment seek-
ing from 25 population surveys sampling 172 413 women 
have demonstrated a 9% prevalence rate. Based on these 
estimates and the current world population, over 72 million 
women are currently infertile and over 40 million are cur-
rently seeking medical care [1]. More recent sources have 
reported that infertility affects as many as 186 million people 
worldwide, with male infertility contributing to over half of 
all cases of global childlessness [2]. Poland lacks detailed epi-
demiological data concerning infertility. Rough calculations 
have estimated that over one million couples are affected 
by infertility and approximately 200 000 couples annually 
seek medical help. Noteworthy, stress which accompanies 
the diagnosis of infertility is on a par with the diagnosis of 
acute myocardial infarction or neoplastic disease. The only 
truly successful therapy of infertility includes pregnancy 
and live birth.
The therapy of infertility should precisely target the 
diagnosed cause of infertility, applying methods which guar-
antee the highest chance for pregnancy and delivery. At 
present, three main therapeutic strategies include pharma-
cological therapy, surgical therapy (preferably endoscopic 
techniques), and assisted reproductive technology (ART). 
Recent decades have witnessed great progress in ART, re-
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sulting in successful treatment of the previously untreatable 
cases. Regardless, social research to counterbalance the 
dominance of biomedical studies, is necessary, particularly 
with regard to expectations of infertile couples in ART [3].
In order to describe the current possibilities of ART in 
reproductive medicine, it seems prudent to briefly demon-
strate the milestone achievements in that field. After the 
birth of Louise Brown in 1978 [4], other children were born 
in different countries, including Australia, the United States, 
France, and Sweden. Ultrasonographic techniques have 
been adopted to evaluate ovarian follicles [5], controlled 
ovarian hyperstimulation with clomiphene citrate, and 
with menopausal gonadotrophins has been introduced [5], 
agonist GnRH has been applied in stimulation protocols [6], 
oocyte retrieval has been performed under ultrasonographic 
guidance [7], and the first live birth after embryo freezing [8], 
as well as after ultra-rapid embryo freezing [9] have been 
reported. Significant progress in the treatment of the male 
factor of infertility was made in 1988, when pregnancy and 
live birth after microsurgical epididymal sperm aspiration 
(MESA) was reported [10], followed by live birth after in-
tracytoplasmic sperm injection (ICSI) four years later [11]. 
In vitro maturation (IVM) of immature oocytes was another 
important step in the development of ART [12]. Since 1992, 
recombinant gonadotrophins have been introduced to the 
ovarian hyperstimulation protocols [13]. 1999 marked the 
beginning of the preimplantation diagnostic processes [14], 
and first live birth after biopsy of the blastocyst occurred 
three years later [15]. In 2004, the first baby after ortho-
tropic transplantation of cryopreserved ovarian tissue was 
born [16], allowing for the development of fertility pres-
ervation methods. 
The abovementioned ‘milestones’ in the field of repro-
ductive medicine are merely some examples of ideas, their 
realization, and overwhelming progress in technology, 
which have accompanied the diagnosis and treatment of 
infertility. Still, these achievements constitute a suitable 
background for the presentation of the contemporary pos-
sibilities of ART. 
Fertility preservation in young cancer patients as well as 
delayed motherhood, when the ovaries have been affected 
by the aging process, has been given much attention. Mod-
ern oncology has enabled over 80% of young people with 
cancer to survive. However, cancer treatment with poten-
tially gonadotoxic therapies is often detrimental to the re-
productive function. Patients or parents should be informed 
about fertility preservation options before treatment com-
mencement using gonadotoxic therapy. Well-established 
and confirmed methods of fertility preservation include 
sperm cryopreservation for men and embryo or oocyte 
cryopreservation for women. Cryopreservation and trans-
plantation of the ovarian cortex and testicular tissue remain 
to be investigated, with very promising results. Ovarian tis-
sue can be easily obtained using laparoscopic techniques, 
without significant delay in gonadotoxic treatment [17]. 
Fertility preservation in women with cervical, endometrial 
and ovarian cancers is provided by both, fertility-sparing 
surgery and ART [18]. According to the literature, prevention 
of fertility in women with gynecological cancers is possible 
without disturbing the oncological safety [19].
The so-called ‘absolute untreatable uterine factor’, which 
affects 3–5% of the general population, is among the causes 
of infertility [20]. In cases when the affected woman rejects 
the idea of surrogacy or adoption, uterine transplantation 
remains the only solution. The development of surgical 
techniques and progress in transplantation immunology 
are the reasons behind the recent addition of a uterus to 
the list of organs successfully transplanted in humans [21]. 
Numerous animals, including rats, mice, rabbits, pigs, sheep 
and primates have been used as experimental models in the 
last decade. A significant number of attempts on humans 
has been performed in Turkey. Literature data revealed 
11 subjects yielding positive pregnancy test but no live 
births. The first live birth after uterus transplantation took 
place in Sweden. Uterus transplantation is a very specific 
procedure and after the delivery of the child/children, the 
uterus has to be removed. Such method of treating absolute 
infertility is prudent only in situations when a blastocyst had 
been achieved and cryopreserved earlier. The procedure, 
although controversial, is an ethically acceptable solution 
in cases of absolute uterine infertility [21].
Advanced maternal age increases the chances of an an-
euploid pregnancy and, as a result, the risk of producing 
an embryo with a genetic disease. Chromosomal defects 
also have an evident impact on the effectiveness of ART. 
Recently, a new generation of preimplantation genetic 
screening (PGS) tests has been introduced, the so-called 
PGS.2. Various aspects are extensively discussed, including 
the indications, the developmental stage, i.e. which material 
should be studied and which molecular techniques should 
be used [23, 24]. CRISP-Cas9 (clustered regularly interspaced 
short palindromic repeats with the molecular structure of 
enzyme Cas9) is the most advanced method of preimplan-
tation diagnosis, allowing for prevention of mitochondrial 
diseases. Together with mitochondrial replacement therapy, 
it has become a promising tool to prevent transmission in pa-
tients with higher mutant mitochondrial loads [25, 26]. While 
the fertilized egg inherits its nuclear DNA from both parents, 
the origin of mitochondrial DNA is exclusively maternal and 
in human reproduction it is associated with a broad range 
of transmitted debilitating and fatal disease. Mitochondrial 
replacement techniques have been successfully introduced 
as a solution to the problem. It is known as the ‘three-parent 
technique’. Although the treatment is legal in England and 
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has been approved by the FDA in the US, it is the source of 
much controversy in many countries [28, 29, 36].
The abovementioned tools of modern reproductive 
medicine with the use of ART, although sometimes gen-
erating spectacular results, are not without certain limita-
tions. At present, there are commonly accepted measures 
of infertility treatment. A baby to take home or a live birth 
per cycle are the gold standards. Also, the safety measures in 
ART are not neglected or omitted. Still, the most significant 
limitation is the effect of therapy. A 25% rate of live births 
per cycle is believed to be a ‘good’ success rate. Nevertheless, 
the 75% ‘failure’ rate remains a fact. Stress accompanying 
an ineffective procedure is extremely high, comparable to 
the initial diagnosis of infertility. The cost of the procedure is 
considerable and should not be ignored, especially in Polish 
conditions. Most recent data on the population of almost 
180 000 women have demonstrate the chance of a live birth 
after 3 complete cycles to be 42.3% [30], which is consistent 
with other publications. The chances for a live birth after 3, 6, 
and 12 cycles were 52%, 72% and 85%, respectively, almost 
the same as in natural procreation [31]. The most limiting 
factor in an effective ART therapy is implantation failure, 
responsible for over 72% of all failures. Human implantation 
is a complex process, requiring synchrony between a healthy 
blastocyst and a functionally receptive endometrium. ‘En-
dometrial receptivity’ is described as temporary and excep-
tional sequence of events and factors which decide that 
an embryo can implant. The implantation takes place during 
the so-called ‘endometrial window of implantation’ (WOI), 
which lasts 4–5 days, with the general assumption that it 
starts 6–10 days after the ovulation and can be identified 
using morphological and biochemical markers [32, 33, 34]. 
In clinical practice, non-invasive methods of assessing endo-
metrial receptivity are very much appreciated. Transvaginal 
ultrasonography 2/3D power Doppler has been proposed 
as a useful tool in the assessment of endometrial receptiv-
ity. It is possible to identify patients with bad prognosis by 
measuring the thickness and structure of the endometrium 
and also the endometrial and sub-endometrial blood flow 
[32, 35]. As a result of much extensive research, new tests 
have been developed as molecular diagnostic tools. Such 
tests allow to identify delayed WOI as well as advanced WOI, 
allowing to personalize embryo transfer. Endometrial func-
tion test (EFT) evaluates endometrial expression of cyclin E 
and p27, another one is based on the evaluation of MAG 
(a substance excreted by endometrial cell before the ovula-
tion). Still, the research continues to develop a test based on 
a single molecular marker. The list of potential candidates 
is long, based on temporary expression of many proteins 
during the implantation window [37, 38].
When defective endometrial receptivity is diagnosed, 
strategies for improving the receptivity are proposed, mostly 
in cases with ART treatment. Four main strategies may be 
differentiated. First, development of ovarian stimulation 
protocols causing minimum reduction in endometrial re-
ceptivity, or even increasing it, is advised. Promising results 
have been reported when clomiphene citrate was not used 
in ovarian stimulation protocols or by vaginal supplemen-
tation of estradiol and progesterone gel [32, 39]. Second, 
freezing of all embryos and performing embryo transfer in 
subsequent natural cycles are recommended to avoid the 
negative influence of the endometrium during stimulated 
cycles [40], but this strategy is not commonly appreciat-
ed [32]. Third, improvement of uterine vascularization by 
changing the uterine and the ovarian blood flow by treating 
patients with low dose aspirin, with nitric oxide donors like 
l-arginine, with intravaginal administration of sildenafil are 
mentioned [32, 41]. Fourth, in order to eliminate all function-
ally and anatomically pathological conditions, treatment 
of the luteal phase defects by removal of fibroids from the 
uterine cavity or intrauterine adhesions, and of hydrosalpinx 
are suggested [32].
The literature offers numerous reports about prognostic 
factors associated with the outcomes of in vitro fertilization 
(IVF), such as maternal age and ovarian ageing, diagnosis, and 
the ovarian reserve. At the same time, relatively little atten-
tion has been paid to lifestyle and IVF outcomes. Smoking, 
alcohol consumption, bad nutritional habits, caffeine intake, 
exercise and exposure to toxic bisphenols are evidently as-
sociated with lower rates of IVF success [42]. Also, exposure to 
power-frequency magnetic field and its impact on reproduc-
tive health in humans needs further research as well.
ART has been the source of a number of successes, some 
of them rather spectacular, but the problem of higher ef-
ficacy is of the outmost importance. It is a well-known fact 
that not all infertile couples may be successfully treated, 
hence the discovery of new, precise ‘predictors’ of an indi-
vidual prognosis has become the greatest challenge in the 
field of reproductive medicine.
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